Pinnacle West Asset Management Inc. Increases Stake in Sanofi (NASDAQ:SNY)

Pinnacle West Asset Management Inc. boosted its stake in shares of Sanofi (NASDAQ:SNY) by 12.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,600 shares of the company’s stock after acquiring an additional 500 shares during the quarter. Pinnacle West Asset Management Inc.’s holdings in Sanofi were worth $222,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of SNY. Synergy Asset Management LLC purchased a new position in Sanofi during the fourth quarter valued at approximately $25,000. McClarren Financial Advisors Inc. raised its position in Sanofi by 952.6% during the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after acquiring an additional 543 shares in the last quarter. Concord Wealth Partners grew its holdings in Sanofi by 157.8% in the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after purchasing an additional 363 shares during the period. Fortitude Family Office LLC grew its holdings in Sanofi by 708.6% in the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock valued at $43,000 after purchasing an additional 659 shares during the period. Finally, Sunbelt Securities Inc. raised its stake in shares of Sanofi by 72.1% during the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after buying an additional 313 shares during the period. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Stock Up 2.1 %

Shares of NASDAQ SNY opened at $54.89 on Wednesday. The company’s 50-day simple moving average is $51.22 and its 200-day simple moving average is $52.56. Sanofi has a 52-week low of $45.22 and a 52-week high of $58.97. The firm has a market cap of $139.30 billion, a price-to-earnings ratio of 22.04, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Equities analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on SNY shares. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Finally, Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Two analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $60.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.